PMV Pharmaceuticals has been granted a patent for compounds and methods to restore wild-type function to p53 mutants in cancer cells. The compounds can bind to mutant p53, enabling it to bind DNA and activate tumor suppression pathways, potentially reducing cancer progression. GlobalData’s report on PMV Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on PMV Pharmaceuticals, Targeted cancer therapy was a key innovation area identified from patents. PMV Pharmaceuticals's grant share as of January 2024 was 13%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11814373B2) discloses a compound of a specific formula, as outlined in the claims. The compound described in the patent consists of various substituents, including alkyl, alkenyl, aryl, heteroaryl, and heterocyclyl, which can be either substituted or unsubstituted, or hydrogen. Additionally, the compound includes specific configurations where R16 and R17 can be independently hydrogen, alkyl, aryl, heteroaryl, or heterocyclyl, with R17 potentially being substituted aryl, such as phenyl with various substituents like sulfoxide, carboxyl, amide, amino, alkyl, alkoxy, hydroxy, halo, cyano, or heterocyclyl.
Furthermore, the patent details variations in the compound structure, with R4 being aryl, heteroaryl, or heterocyclyl substituted with at least fluoro-. Specific examples are provided, such as R4 being substituted piperidinyl. The claims also mention the compound in different configurations, denoted by numbers 12 to 16, showcasing the versatility and potential applications of the disclosed compound. This patent highlights the unique chemical composition and structural features of the compound, paving the way for potential advancements in various fields where such compounds could be utilized.
To know more about GlobalData’s detailed insights on PMV Pharmaceuticals, buy the report here.
See Also:
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
